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Objective: To assess the effects of 2 months of treatment with Femarelle for climacteric syndrome in
Taiwanese postmenopausal women.
Materials and methods: A multi-center, open-label trial of 260 postmenopausal women, age  45 years
with vasomotor symptoms. Women were enrolled after obtaining a detailed medical history and a
thorough physical examination. They then received Femarelle (640 mg/d) twice daily for 8 weeks. The
primary outcome was the changes in the frequency and severity of hot ﬂushes from baseline to 4 weeks
(1 month) and 8 weeks (2 months). Changes of general climacteric syndrome were assessed using a
modiﬁed climacteric scale designed by Greene.
Results: The frequency and severity of hot ﬂushes were signiﬁcantly improved with Femarelle use
(p < 0.001). After 8 weeks of treatment, the percentage of women with various climacteric syndromes
was reduced (from 100% to 20.9% for hot ﬂushes, from 97.7% to 87.9% for psychological symptoms, from
93.8% to 78.8% for somatic symptoms, and from 87.8% to 74.9% for sexual symptoms). General climacteric
syndrome scores also signiﬁcantly decreased, from 20.8 ± 0.7 at the time of enrollment to 12.9 ± 0.7 after
8 weeks of Femarelle treatment (p < 0.0001). Participants experienced improvement of various
climacteric symptoms and signs after 8 weeks of treatment (75.1% for hot ﬂushes, 68.7% for psychological
symptoms, 70.6% for somatic symptoms, and 69.0% for sexual problems respectively). After 4 weeks and
8 weeks of treatment with Femarelle, patients showed statistically signiﬁcant improvement in climac-
teric symptoms (p < 0.0001). Three women (1.2%) withdrew from the study after 4 weeks of treatment
due to adverse effects.
Conclusion: Femarelle signiﬁcantly improved climacteric symptoms in Taiwanese postmenopausal
women. However, further evaluation is needed regarding the safety of long-term consumption.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Hormone therapy (HT) has been recognized as the most effec-
tive treatment for climacteric syndrome, especially hot ﬂushes.s and Gynecology, Keelung
Keelung 20401, Taiwan.
).
bstetrics & Gynecology. PublishedHowever, reports from the Women Health Initiative trial [1,2] and
the Million Women Study [3] have raised concerns regarding the
side effects of HT. Therefore, the need for a complementary and
alternative treatment to relieve climacteric symptoms has been
extensively studied.
Phytoestrogen is generally deﬁned as any plant substance or
metabolite that induces biological responses through mimicking or
modulating the actions of endogenous estrogens, usually byby Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
Table 1
Baseline characteristics of enrolled women.
Variables (n ¼ 260) Mean ± SD/n (%)
Mean age (y) 53.0 ± 5.9 (45e77)
Mean body weight (kg) 57.4 ± 8.0 (37e83)
Smoking 12 (12.7)
Mean age of menopause (y) 48.6 ± 5.0 (26e59)
Natural cessation of menstruation (n ¼ 250)a 197 (87.8)
Surgical cessation of menstruation (n ¼ 250)a 53 (21.2)
SD ¼ standard deviation.
a Ten patients did not answer the question.
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trogenic so it has been proposed that phytoestrogens may play a
role in estrogen-related conditions, such as menopausal symptoms
and postmenopausal osteoporosis. Phytoestrogens can be generally
classiﬁed into the following groups: isoﬂavones, coumestans, and
lignans. Isoﬂavones, which have been the most extensively studied
phytoestrogens, are found predominately in soybeans and soy
product-containing foods [4].
Although the present available data on using isoﬂavone as a
form of treatment is either still inconclusive or only shows a slight
improvement in symptomatic relief, the general trend focuses on
using soy isoﬂavones as a supplement. However, isoﬂavones cannot
represent all phytoestrogens so further evaluation regarding the
effects of phytoestrogens with different compositions, methods
used to isolate the various components of phytoestrogens, con-
centrations of bioavailable phytoestrogens, and the effects of the
use of a combination of various phytoestrogens in addition to iso-
ﬂavones may be needed.
Unlike general soy isoﬂavone products, Femarelle (Se-cure
Pharmaceuticals, Yavne, Israel) is the combination of phytoestro-
gen compounds aside from isoﬂavone, such as lignans and cou-
mestans. It has been reported that Femarelle is manufactured with
a unique isolation enzymatic process to ensure that the entire
family of phytoestrogen compounds, as is found in tofu, remains in
their naturally intact form and is therefore able to increase its
bioavailability to the body [5,6]. As such, Femarelle is capable of
providing high efﬁcacy and selectivity and has been described as a
“new phyto-selective estrogen receptor modulator” [7,8].
The purpose of the present study is to assess the efﬁcacy of
Femarelle for the relief of hot ﬂushes, as well as of general meno-
pausal symptoms in postmenopausal women.
Materials and methods
Between December 2012 and January 2014, a multicenter, open-
label clinical trial of Femarelle was conducted. Two hundred and
sixty postmenopausal women, enrolled at seven medical hospitals
in Taiwan, met the inclusion criteria and did not transgress the
exclusion criterion. The institutional review board or ethical review
board at each of the seven institutions approved the protocol of the
present trial and the trial was conducted in accordance with their
protocols. All patients provided written informed consent prior to
their enrollment.
At enrollment, each patient underwent a detailed medical and
gynecological history taking, which was then followed by a
physical examination. The inclusion criteria were listed as follows:
peri- and postmenopausal women should be aged  45 years and
should at least have hot ﬂush symptoms, women who are not
currently taking HT or have stopped HT for > 1 month, and have
not taken phytoestrogen supplements for > 1 week. Participants
who have experienced cessation of menstruation for < 1 year
received blood hormone evaluation and met the following criteria
for enrollment: follicle-stimulating hormone  35 mIU/mL and
estradiol < 30 pg/mL. Exclusion criteria included women with
soybean allergy and those with a history of breast cancer and/or
endometrial cancer.
The present trial consisted of a 1-week screening period and
a 8-week treatment period. Throughout the treatment period,
Femarelle (640 mg/d) was orally administered twice daily to
each participants for 8 weeks. Participants visited the hospital a
total of three times (1st visit at screening, 2nd visit at Week 5
after completion of 4 weeks of medication, and 3rd visit at Week
9 after completion of 8 weeks of medication) for general eval-
uation and to return completed questionnaires at each of the
visits.Assessment of efﬁcacy
Assessments included questionnaires regarding the frequency
and severity of hot ﬂushes and symptomatic changes of general
menopausal syndrome, according to women's menopause health
manual designed by the Health Promotion Administration from the
Ministry of Health and Welfare, Executive Yuan in 2011. This scale
was modiﬁed from the climacteric scale designed by Greene [9].
The data of hot ﬂushes were collected by patient diaries. This
climacteric scale takes into consideration common climacteric
symptoms, including vasomotor symptoms (hot ﬂushes), psycho-
logical symptoms (irritability, depression, loss of interest, anxiety,
sleep disturbances, and fatigue), somatic symptoms (dizziness,
headache, back pain, joint pain, myalgia, increased facial hair, and
skin dryness), and sexual symptoms (decreased libido, decreased
sexual acceptance, vaginal dryness, and dyspareunia). For each of
the symptomsmentioned above, a score of 0, 1, 2, or 3 was given for
no, mild, moderate, or severe intensity respectively.
The primary endpoint for efﬁcacy was the changes in the fre-
quency and severity of hot ﬂushes from baseline to Week 4 and
Week 8. The secondary endpoints for efﬁcacy were the changes in
the general climacteric syndrome from baseline to Week 4 and
Week 8.
Statistical analysis
Descriptive statistics were summarized for the characteristics of
study variables, including frequencies, percentages for categorical
data, median, means, and standard deviation for continuous vari-
ables. Comparison among groups categorized by nominal variables,
such as other therapy, cause of cessation, and last menstrual period
time, were performed using analysis of variance. Follow-up pair-
wise comparisons such as 2-sample t test and 2-sample Chi-square
or Fisher's exact tests for continuous and categorical variables were
made if overall tests were signiﬁcant. Trend of levels in ordinal
outcome, such as intensity level of hot ﬂashes was estimated and
tested using the general linear regression method. Generalized
Estimating Equations method was used to estimate the time effect.
All tests were two-sided and a p value < 0.05 was considered as
statistical signiﬁcance. All statistical intention-to-treat analyses
were performed using SAS version 9 (SAS Institute Inc., SAS Campus
Drive, Cary, North Carolina 27513, USA).
Results
From December 2012 until January 2014, there were 260
women who met the initial criteria for inclusion into our analysis.
Data on their current age, age atmenopause, bodyweight, smoking,
and causes of menstrual cessation are summarized in Table 1. As
shown in Figure 1, of these 260 participants, complete data are
available for 236 of the women at the conclusion of 4 weeks of
treatment and for 221 women at the end of 8 weeks of treatment.
Most of the women who withdrew from the study were due to
F.-P. Chen et al. / Taiwanese Journal of Obstetrics & Gynecology 55 (2016) 336e340338personal reasons or adverse side effects. Reported adverse side
effects during the trial included breast tenderness (n ¼ 5), nausea
(n ¼ 3), abdominal distention (n ¼ 2, withdrawal after 4 weeks of
treatment), and headache (n ¼ 2, 1 withdrawal after 4 weeks of
treatment). The withdrawal rate due to adverse effects was about
1.2%.
In addition to hot ﬂushes, other symptoms and signs experi-
enced by the patients before and after treatment, according to the
climacteric scale, are summarized in Table 2. After treatment, the
various climacteric scores were decreased (1.82 ± 0.05, 1.40 ± 0.05,
and 1.06 ± 0.05 for hot ﬂushes; 7.31 ± 0.30, 4.83 ± 0.27, and
4.16 ± 0.26 for psychological symptoms; 6.63 ± 0.29, 4.76 ± 0.27,
and 4.25 ± 0.24 for somatic symptoms; and 5.03 ± 0.25, 3.97 ± 0.27,
and 3.38 ± 0.24 for sexual symptoms). The percentage of women
with various climacteric syndromes was also reduced (100%, 40.2%,
and 20.9% for hot ﬂushes; 97.7%, 93.9%, and 87.9% for psychological
symptoms; 93.8%, 84.5%, and 78.8% for somatic symptoms; and
87.8%, 83.1%, and 74.9% for sexual symptoms).
During the course of the 8-week treatment, the frequency and
intensity of hot ﬂushes improved day by day after Femarelle use
(Figure 2). There is a strong correlation between the duration of
Femarelle use and both improvement of frequency (R2: 0.952,
p < 0.001) and intensity of hot ﬂushes (R2: 0.933, p < 0.001).
Using a Generalized Estimating Equations model, the scores of
general climacteric syndrome were signiﬁcantly decreased from
20.8 ± 0.7 at enrollment to 15.5 ± 0.6 after 4 weeks of treatment
with Femarelle and 12.9 ± 0.7 after 8 weeks of Femarelle use
(p < 0.0001). In addition, the percentages of the participants
experiencing improvement of various climacteric symptoms after
4 weeks and 8 weeks of treatment were 59.8% and 75.1% for hot
ﬂushes, 50.8% and 68.7% for psychological symptoms, 61.0% and
70.6% for somatic symptoms, and 56.7% and 69.0% for sexual
problems respectively (Figure 3). The differences in the percentage
of symptomatic improvement as compared with baseline, as well
the correlation between increased symptomatic improvement and4 wk
a One patient had a nausea sensation occasionally during the 8-week treatment.
b One patient complained of headaches occasionally.
c Two patients complained of breast tenderness.
d Three patients had breast tenderness and two patients complained of nausea.
e Three patients withdrew from the study after 4 weeks of treatment, two due to 
abdominal distention, and one due to headache.
HP = participating medical hospital.
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Figure 1. Flow chart for patients enrolled in this study.duration of use (4 weeks vs. 8 weeks), depicted the signiﬁcant ef-
fects of Femarelle use (p < 0.0001).
Discussion
With an increase in life expectancy, it is inevitable that most
women will suffer from climacteric symptoms. With regard to the
conclusion of Women Health Initiative trial [1,2] and the Million
Women Study [3], complementary and alternative medicines are
also becoming increasingly popular. The present study demon-
strates that Femarelle, a combination of different phytoestrogen
compounds, not only signiﬁcantly improves the frequency and
intensity of hot ﬂushes, but also helps with other climacteric
syndrome symptoms, including psychological, somatic, and sex-
ual problems. Although such efﬁcacy is encouraging, several
additional factors regarding these results still need to be
considered.
Hot ﬂushes are the most common symptoms in peri- and
postmenopausal women and can interfere with quality of life and
disrupt sleep. Thus, most menopausal women seek medical
support due to hot ﬂushes. It has been reported that 10e25% of
Chinese women and 10e20% of Indonesian women have hot
ﬂashes compared with 58e93% of Western women [10]. It has
been proposed that this lower prevalence of hot ﬂashes in Asian
women when compared with their Western counterparts is, at
least in part, related to the consumption of a diet rich in soy
phytoestrogen [11,12]. Soy is a main source of phytoestrogens,
especially isoﬂavone. A meta-analysis of all randomized,
controlled trials of isoﬂavone supplementation showed that iso-
ﬂavone supplementation may produce a slight to modest reduc-
tion in the number of daily ﬂushes in menopausal women and
that this beneﬁt may be more apparent in womenwho experience
a higher number of ﬂushes per day. By contrast, another recent
meta-analysis reviewing 11 trials on soy isoﬂavones extracts did
not show efﬁcacy in the treatment of hot ﬂushes [13]. Several
factors related to these conﬂicting results have been considered,
including isoﬂavones' relatively short half-life of 6e12 hours [14].
Thus, the efﬁcacy of isoﬂavone combined with other phytoes-
trogens has also been studied. A trial conducted by Sammartino
et al [15] demonstrated that the combination of 60 mg isoﬂavones
and lignans had a signiﬁcant reduction in hot ﬂushes compared
with placebo. The authors considered that the reduction of
vasomotor syndrome may be related to the observation that
isoﬂavones are absorbed earlier than lignans are. Femarelle is the
combination of isoﬂavone, lignans, and coumestans. The present
study also conﬁrms the efﬁcacy of combined phytoestrogens
therapy, not only through the signiﬁcant relief of hot ﬂushes in
75.1% of women after 8 weeks of treatment, but also through the
signiﬁcant reduction of the frequency and intensity of post-
menopausal hot ﬂushes. Other studies also demonstrated similar
results, in which women who received Femarelle for 12 months
noted a 76% reduction in vasomotor symptoms [16], as well as a
signiﬁcant improvement in the severity of hot ﬂushes/night
sweats (Femarelle baseline 2.17 ± 0.94, ﬁnal 0.75 ± 0.69,
p < 0.001) [17].
Except for its effects on hot ﬂushes, a review of the data from the
more rigorous trials show that isoﬂavones do not improve other
menopausal symptoms [18], such as psychological, somatic, and
sexual symptoms. It has been demonstrated that various phytoes-
trogens have different effects on the binding afﬁnity and trans-
activational properties of estrogen receptors in different tissues and
cell types [19]. Thus, as selective estrogen receptor modulators,
different phytoestrogens may possess compound-speciﬁc estro-
genic/antiestrogenic effects on various tissues. Most of the studies
also revealed that isoﬂavones do not relieve vaginal atrophy
Table 2
The present menopausal symptoms of enrolled women.
Climacteric symptoms No treatment score (women %) 4 wk score (women %) 8 wk score (women %)
Vasomotor symptoms: 1.82 ± 0.05 (100) 1.4 ± 0.05 (40.2) 1.06 ± 0.05 (24.9)
Hot ﬂushes 1.82 ± 0.05 (100) 1.4 ± 0.05 (40.2) 1.06 ± 0.05 (24.9)
Psychological symptoms: 7.31 ± 0.30 (97.7) 4.83 ± 0.27 (93.9) 4.16 ± 0.26 (87.9)
Irritability 1.04 ± 0.06 (71.0) 0.68 ± 0.05 (52.7) 0.57 ± 0.05 (46.0)
Depression 1.13 ± 0.06 (74.4) 0.73 ± 0.05 (58.9) 0.66 ± 0.05 (54.5)
Feeling of loss 1.05 ± 0.06 (70.8) 0.67 ± 0.05 (52.0) 0.55 ± 0.05 (45.2)
Nervous 1.24 ± 0.07 (73.6) 0.85 ± 0.05 (65.7) 0.75 ± 0.05 (59.5)
Sleep disturbances 1.54 ± 0.07 (79.6) 1.10 ± 0.06 (71.6) 0.97 ± 0.07 (64.9)
Sense of weakness or fatigue 1.44 ± 0.06 (84.0) 0.98 ± 0.05 (72.4) 0.75 ± 0.05 (61.6)
Somatic symptoms: 6.63 ± 0.29 (93.8) 4.76 ± 0.27 (84.5) 4.25 ± 0.24 (78.8)
Dizziness 0.96 ± 0.06 (69.8) 0.65 ± 0.05 (51.3) 0.61 ± 0.05 (51.1)
Headache 1.03 ± 0.06 (70.3) 0.76 ± 0.05 (60.7) 0.63 ± 0.06 (48.7)
Back pain 1.15 ± 0.06 (75.9) 0.86 ± 0.06 (63.9) 0.75 ± 0.05 (58.9)
Joint pain 1.32 ± 0.06 (79.2) 0.90 ± 0.06 (64.2) 0.80 ± 0.06 (61.5)
Myalgia 1.10 ± 0.06 (70.6) 0.81 ± 0.06 (60.8) 0.67 ± 0.05 (53.1)
Increased facial hair 0.22 ± 0.04 (14.8) 0.14 ± 0.03 (12.5) 0.15 ± 0.03 (13.9)
Skin dryness 1.12 ± 0.06 (71.2) 0.90 ± 0.06 (64.7) 0.75 ± 0.06 (58.2)
Sexual symptoms: 5.03 ± 0.25 (87.8) 3.97 ± 0.27 (83.1) 3.38 ± 0.24 (74.9)
Decreased libido 1.43 ± 0.07 (80.5) 1.10 ± 0.07 (69.0) 0.92 ± 0.07 (61.6)
Decreased sexual acceptance 1.35 ± 0.07 (76.7) 1.13 ± 0.07 (69.3) 0.92 ± 0.07 (60.0)
Vaginal dryness 1.46 ± 0.07 (79.3) 1.12 ± 0.07 (72.1) 0.93 ± 0.06 (64.9)
Dyspareunia 1.13 ± 0.07 (64.1) 0.91 ± 0.07 (55.3) 0.78 ± 0.07 (51.9)
Figure 2. The trend of the frequency and intensity in hot ﬂushes during 8 weeks of
treatment with Femarelle were determined and tested using linear regression analysis
and generalized estimating equation analysis.
Figure 3. Percent of patients who reported improvement of major climacteric symp-
toms at 4 weeks and 8 weeks of treatment with Femarelle. Statistical signiﬁcance was
noted by analysis using generalized estimating equations (p < 0.0001).
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of using a combined isoﬂavone and lignan supplement on vaginal
epithelium. That study observed a signiﬁcant reduction in vaginal
pH from 7.7 ± 2.2 at baseline to 4.9 ± 1.4 at Week 12 (p < 0.0001)and a signiﬁcant improvement in the maturation index in 10 out of
12 women. Although this study was limited by a small patient
population and a relatively short duration, differences compared
with previous reports on isoﬂavone use for vaginal atrophy may be
related to the different afﬁnities and transactivational potencies of
phytoestrogens in different tissues and thereby resulting in tissue-
speciﬁc variability. However, the present study also revealed a
signiﬁcant reduction in vaginal dryness score (baseline 1.49 ± 0.07,
at 4 weeks 1.14 ± 0.07, at 8 weeks 0.94 ± 0.07, p < 0.0001) and
dyspareunia (baseline 1.15 ± 0.08, at 4 weeks 0.93 ± 0.08, at
8 weeks 0.81 ± 0.07, p < 0.0001; data not shown).
Researches regarding the use of a combination of phytoes-
trogens, such as Femarelle, compared with HT for its effectiveness
on climacteric syndrome have been conducted. In an animal study
using ovariectomized rats, Femarelle increased allopregnanolone
and b-endorphin levels in the brain, which were comparable to
those of ovariectomized rats treated with estradiol [24]. These
ﬁndings may, in part, explain the clinical effect of Femarelle on
menopausal symptoms. In the present study, aside from hot
ﬂushes, a signiﬁcant reduction of psychological, somatic, and sexual
problems related to brain-derived symptoms, such as sleep
disturbance, mood changes, and sexual dysfunction, was also
noted. In addition, it was also reported that when menopausal
symptoms were assessed using the Kupperman index, a signiﬁcant
decrease in score was noted in both DT56a (Femarelle) and HT
treatment for 12 months (mean difference in Kupperman score,
DT56a group: 3.98, HT group: 5.601, no treatment group: þ1.76,
p < 0.001) [17]. This study also demonstrated a signiﬁcant decrease
in modiﬁed Greene climacteric scale score.
In all of the literature reviewed, few side effects have been re-
ported after phytoestrogen use, with the most serious related to
gastrointestinal discomfort [25]. The present study also revealed
rare adverse effects, including nausea, abdominal distention,
headache, and mastalgia. Even after reviewing previous reports,
there is little evidence that phytoestrogens cause endometrial hy-
perplasia or other adverse health effects when used at routine
doses for a short period of time in postmenopausal women [26].
However, there is no information available regarding the effects of
long-term consumption.
In conclusion, Femarelle was found to signiﬁcantly relieve hot
ﬂushes and other menopausal symptoms within the 1st 4 weeks of
F.-P. Chen et al. / Taiwanese Journal of Obstetrics & Gynecology 55 (2016) 336e340340treatment and this trend continued following 8weeks of treatment.
However, limitations of this study included the absence of a control
group and a short period of treatment. Although Femarelle can be
considered as an alternative treatment to HT for postmenopausal
women with climacteric syndrome, safety of long-term consump-
tion warrants further evaluation.
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